TEL AVIV, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that on September 25, 2025, the stockholders of N2OFF, Inc. (NASDAQ: NITO) (“N2OFF”) voted on and approved, among other things, the proposed acquisition of SciSparc’s majority owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”). This important ...

Company Overview - Sutro Biopharma, Inc. is focused on the discovery and development of precisely designed cancer therapeutics, particularly antibody drug conjugates (ADCs) [3] - The company utilizes innovative technology, including cell-free XpressCF, to enhance patient benefits and experiences [3] - Sutro is advancing a robust early-stage pipeline of novel exatecan and dual-payload ADCs, supported by high-value collaborations and industry partnerships [3] Upcoming Events - Sutro management will participate in two investor conferences: - The Citizens Life Sciences Conference on May 7-8, 2025, in New York, NY [2] - BofA Securities 2025 Health Care Conference on May 13-15, 2025, in Las Vegas, NV [2] - Webcasts of the presentations will be available on the company's website, with archived replays accessible for at least 30 days post-event [2]